Needles and the damage done: Reasons for admission and financial costs associated with injecting drug use in a Central London Teaching Hospital

Journal of Infection

Volumn 66, Issue 1, 2013, Pages 95-102

  Marks, Michael ^a   Pollock, Emily ^a   Armstrong, Margaret ^a   Morris Jones, Stephen ^b   Kidd, Michael ^b   Gothard, Philip ^a   Noursadeghi, Mahdad ^c   Doherty, Justin F ^a  

^a HOSPITAL FOR TROPICAL DISEASES   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Blood borne viruses; Cost; Injecting drug use; Skin and soft tissue infections; Substance misuse

Indexed keywords

ADULT; ARTICLE; BACTEREMIA; COHORT ANALYSIS; DISRUPTIVE BEHAVIOR; DRUG MISUSE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEPATITIS B; HEPATITIS C; HOSPITAL ADMISSION; HOSPITALIZATION COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL HEALTH SERVICE; PNEUMONIA; RETROSPECTIVE STUDY; SKIN INFECTION; SOFT TISSUE INFECTION; TEACHING HOSPITAL; UNITED KINGDOM;

ADULT; CHI-SQUARE DISTRIBUTION; FEMALE; HOSPITALIZATION; HOSPITALS, TEACHING; HUMANS; LENGTH OF STAY; LONDON; MALE; NEEDLESTICK INJURIES; RETROSPECTIVE STUDIES; SEPSIS; SKIN DISEASES, INFECTIOUS; SOFT TISSUE INFECTIONS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84870757297     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.10.004     Document Type: Article

References (19)

1. Hay G., Gannon M., MacDougall J., Eastwood C., Williams K., Millar T. Capture-recapture and anchored prevalence estimation of injecting drug users in England: national and regional estimates. Statistical Methods in Medical Research 2009, 18(4):323-339.
2. Health Protection Agency Unlinked anonymous HIV and viral hepatitis monitoring among IDUs: 2010 update [Internet] 2011, Available from:. http://www.hpa.org.uk/hpr/achive/2010/hpr3010.pdf.
3. Takahashi T.A., Baernstein A., Binswanger I., Bradley K., Merrill J.O. Predictors of hospitalization for injection drug users seeking care for soft tissue infections. Journal of General Internal Medicine 2007 Jan 17, 22(3):382-388.
4. Islam M.M., Topp L., Day C.A., Dawson A., Conigrave K.M. The accessibility, acceptability, health impact and cost implications of primary healthcare outlets that target injecting drug users: a narrative synthesis of literature. International Journal of Drug Policy 2012 Mar, 23(2):94-102.
5. Beaufoy A. Infections in intravenous drug users: a two-year review. The Canadian Journal of Infection Control 1993, 8(1):7-9.
6. Mertz D., Viktorin N., Wolbers M., Laifer G., Leimenstoll B., Fluckiger U., et al. Appropriateness of antibiotic treatment in intravenous drug users, a retrospective analysis. BMC Infectious Diseases 2008, 8(1):42.
7. Palepu A., Tyndall M.W., Leon H., Muller J., O'Shaughnessy M.V., Schechter M.T., et al. Hospital utilization and costs in a cohort of injection drug users. Canadian Medical Association Journal 2001, 165(4):415-420.
8. Atkinson S.R., Paul J., Sloan E., Curtis S., Miller R. The emergence of methicillin-resistant Staphylococcus aureus among injecting drug users. Journal of Infection 2009 May, 58(5):339-345.
9. Huang H., Cohen S.H., King J.H., Monchaud C., Nguyen H., Flynn N.M. Injecting drug use and community-associated methicillin-resistant Staphylococcus aureus infection. Diagnostic Microbiology and Infectious Disease 2008 Apr, 60(4):347-350.
10. Lamagni T.L., Neal S., Keshishian C., Hope V., George R., Duckworth G., et al. Epidemic of severe Streptococcus pyogenes infections in injecting drug users in the UK, 2003-2004. Clinical Microbiology and Infection 2008 Nov 1, 14(11):1002-1009.
11. Hope V.D., Palmateer N., Wiessing L., Marongiu A., White J., Ncube F., et al. A decade of spore-forming bacterial infections among European injecting drug users: pronounced regional variation. American Journal of Public Health 2012 Jan, 102(1):122-125.
12. Schroeter M., Alpers K., Van Treeck U., Frank C., Rosenkoetter N., Schaumann R. Outbreak of wound botulism in injecting drug users. Epidemiology & Infection 2009, 137(11):1602-1608.
13. Bargagli A.M., Hickman M., Davoli M., Perucci C.A., Schifano P., Buster M., et al. Drug-related mortality and its impact on adult mortality in eight European countries. European Journal of Public Health 2006 Apr, 16(2):198-202.
14. Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., Fein A.M., Knaus W.A., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992 Jun, 101(6):1644-1655.
15. Miller M., Cespedes C., Vavagiakis P., Klein R.S., Lowy F.D. Staphylococcus aureus colonization in a community sample of HIV-infected and HIV-uninfected drug users. European Journal of Clinical Microbiology & Infectious Diseases 2003, 22(8):463-469.
16. Health Protection Agency Unlinked anonymous HIV and viral hepatitis monitoring in IDUs - a 20-yr review [Internet] 2011, Available from:. http://www.hpa.org.uk/hpr/archives/2010/hpr1710.pdf.
17. Hope V., Kimber J., Vickerman P., Hickman M., Ncube F. Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England. BMC Infectious Diseases 2008, 8:120.
18. Turner K.M.E., Hutchinson S., Vickerman P., Hope V., Craine N., Palmateer N., et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011 Nov 1, 106(11):1978-1988.
19. British HIV Association National guidelines on HIV testing 2008, British Association of Sexual Health and HIV, British Infection Society, United Kingdom, Available from:. http://www.bhiva.org/HIVTesting2008.aspx.